| Trial ID: | L4636 |
| Source ID: | NCT02782208
|
| Associated Drug: |
Acipimox
|
| Title: |
Lipolytic Effects of GH in Hypopituitary Patients in Vivo
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hypopituitarism|Insulin Resistance|Endocrine System Diseases|Glucose Metabolism Disorders|Metabolic Diseases|Pituitary Diseases|Brain Diseases
|
| Interventions: |
DRUG: Acipimox|DRUG: Placebo|DRUG: GH substitution|OTHER: GH pause
|
| Outcome Measures: |
Primary: Lipolytic activity measured as area under the curve (AUC) for FFA (free fatty acid) before and during clamp-conditions., 1 year | Secondary: GH signaling proteins and gene targets in adipose and skeletal muscle tissues measured by western blotting and qPCR, 1,5 years|Insulin sensitivity as measured by M value and GIR (glucose infusion rate), 6 months|Substrate metabolism as measured by indirect calorimetry, tritiated glucose and circulating hormones and metabolites, 1 year|PDH (pyruvate dehydrogenase) activity in skeletal muscle measured by an PDH activity assay, 1 year
|
| Sponsor/Collaborators: |
Sponsor: University of Aarhus
|
| Gender: |
MALE
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
9
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2016-02-10
|
| Completion Date: |
2016-12-22
|
| Results First Posted: |
|
| Last Update Posted: |
2020-03-26
|
| Locations: |
University Hospital of Aarhus, Aarhus, 8000, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT02782208
|
